How much has Exact Sciences raised?
Exact Sciences is not venture-backed. As of June 2026 it was a public company trading as Nasdaq: EXAS, with $3.25B 2025 of 2025 revenue scale and mature access to public-company financing tools.
- Public status
- Nasdaq: EXAS
- Revenue
- $3.25B 2025
- Funding type
- Public markets
- Disclosed rounds
- Not VC disclosed
- First raised
- Public-company history
- Seller signal
- Enterprise healthcare buyer
Exact Sciences's capital history
Exact Sciences's capital history is public-company funding, operating cash flow, acquisitions, and market access rather than startup rounds.
- 1995Company foundedExact Sciences begins the business that later scales into a public healthcare company.
- Public listingNasdaq: EXAS public-market accessPublic equity and debt-market access replace startup-style venture rounds as the relevant capital lens.
- Portfolio eraPortfolio expansionAcquisitions, divestitures, internal R&D, and manufacturing investments become important capital-allocation tools.
- 2025$3.25B 2025 revenue scaleExact Sciences reported total 2025 revenue of $3.25 billion, up 18%, with Screening revenue of $2.53 billion and Precision Oncology revenue of $717 million.
- Jun 2026Nasdaq: EXAS public companyExact Sciences remains a public enterprise healthcare buyer with mature procurement controls.
Sources:Exact Sciences annual reportsNasdaq: EXAS market data
How much has Exact Sciences raised in total?
Exact Sciences does not have a meaningful current venture-funding total. The company should be evaluated through public equity, operating cash flow, debt capacity, acquisitions, divestitures, partnerships, and retained earnings rather than Seed, Series A, or late-stage venture rounds.
Who are Exact Sciences's investors?
The relevant investors are public-market shareholders, index funds, active healthcare investors, bondholders where applicable, and internal capital allocators. Their focus is durable revenue, margins, cash conversion, pipeline or product execution, regulatory risk, reimbursement exposure, and management's ability to deploy capital at attractive returns.
Why does Exact Sciences's valuation move?
Exact Sciences's valuation moves with growth, margins, cash flow, clinical or regulatory milestones, procedure or prescription trends, test volume, reimbursement, pricing pressure, product cycles, supply reliability, litigation, acquisitions, and investor confidence in management's outlook. Healthcare buyers can still spend during turbulent markets, but approvals become more tied to measurable savings and risk control.
Is Exact Sciences profitable, and will it IPO?
Exact Sciences is already public. Profitability should be assessed from its filings and earnings releases rather than IPO readiness; the practical question is how much cash and management attention can be allocated to new vendors, systems, facilities, clinical programs, commercial expansion, or productivity work.
What does Exact Sciences's funding mean if you sell into them?
The company has enterprise-scale budget capacity, but procurement is mature and evidence-driven. Sellers should expect security review, compliance review, legal negotiation, business-unit sponsorship, and a requirement to prove value in patient outcomes, operating efficiency, revenue capture, supply reliability, cybersecurity, data quality, or risk reduction.
As of June 2026.Sources:Exact Sciences 2025 resultsExact Sciences annual reportsNasdaq: EXAS market data
Exact Sciences — frequently asked questions
